Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pharmacokinetic Study of GSK2982772 Modified Release Formulations
NCT03649412Phase 1Completed
- Sponsor
- GSK
- Start
- Sep 2018
- Primary completion
- May 2019
- Modality
- Orthosteric Ligands
- Countries
- 1
01
Overview
Phase 1, open-label trial of GSK2982772 in autoimmune diseases (2 arms), sponsored by GSK. Primary endpoints: Area Under the Curve From Time Zero to Infinity, Area Under the Curve From Time Zero to Last Measurable Concentration and 6 more. Started Sep 2018; status: completed.
02
Drugs
GSK2982772
03
Conditions
autoimmune diseases
Beyond the preview
Go deeper on NCT03649412.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03649412.